- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07856862
Culturally Adapted Materials to Increase Cervical Cancer Screening Among Polish Women in Iceland
Testing of Culturally Adapted Materials to Enhance Participation in Cervical Cancer Screening Among Polish Women Residing in Iceland
This study tests whether sending Polish women residing in Iceland a culturally adapted invitation letter - tailored in language and messaging to the target group - increases participation in cervical cancer screening compared with a standard, non-adapted invitation letter. Eligible women will be randomly assigned to receive one of the two letter types, and screening participation will be tracked over the following months.
Study Overview
Status
Detailed Description
It has been shown that cervical cancer screening participation remains lower among women with immigrant background, compared to the general population. Translating existing screening materials into the languages of the immigrant groups may not be sufficient to motivate screening participation. However, cultural adaptation of cancer screening materials has been suggested as a potential strategy to facilitate screening attendance.
This study investigates whether a culturally adapted invitation letter increases attendance at cervical cancer screening among Polish women residing in Iceland, compared with the standard invitation letter currently used in the national cervical cancer screening program. The adapted letter was developed in collaboration with a focus group from the target population.
All individuals registered as female in Registers Iceland and aged 23-64 years are eligible for cervical cancer screening in accordance with the national cancer screening guidelines issued by the Directorate of Health. Eligible individuals receive an invitation letter both digitally via the national health portal and by post. All eligible individuals receive digital invitations in Icelandic, English and Polish. Paper invitations are available only in Icelandic. Therefore, the culturally adapted letter will only be sent digitally.
Polish-born women residing in Iceland who are due for routine cervical cancer screening will be randomized 1:1 to receive either the culturally adapted invitation letter or the standard invitation letter.
This trial is intended to generate evidence on whether low-cost intervention, such as the cultural adaptation of existing screening materials, may help reduce disparities in screening uptake.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ásgerður Marteinsdóttir
- Phone Number: +3545136700
- Email: asgerdur.marteinsdottir@heilsugaeslan.is
Study Contact Backup
- Name: Ágúst Ingi Ágústsson
- Phone Number: +3545136700
- Email: agust.ingi.agustsson@heilsugaeslan.is
Study Locations
-
-
-
Garðabaer, Iceland, 210
- Cancer Screening Coordination Center, Primary Health Care of the Capital Area
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals within the target population for the national cervical cancer screening program in Iceland, defined as those registered as female in the population register and aged 23-64 years
- Born in Poland
- Being due to be invited for cervical cancer screening during the study enrolment period, in accordance with the cervical cancer screening guidelines issued by the Directorate of Health.
Exclusion Criteria:
-Individuals who are not eligible for the national cervical cancer screening program in Iceland (non-female, outside the screening age and not due for an invitation (time since last screening attendance)).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Culturally adapted invitation letter
Participants in this arm receive a screening invitation letter which has been culturally adapted, developed with community input. |
Participants randomized to the intervention group will receive a screening invitation letter which has been culturally adapted, developed with community input from individuals in the target group. The letter provides information about cervical cancer screening and has been adapted to the language, cultural context, and communication needs of the target population of Polish women residing in Iceland. The adapted letter retains the essential information contained in the standard invitation while modifying its wording and presentation to improve relevance, understanding, and engagement, with the aim of increasing attendance at cervical cancer screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is. |
|
Active Comparator: Standard cervical cancer screening invitation letter
Participants in this arm receive a standard invitation letter to cervical cancer screening. |
Participants randomized to the control group will receive the standard invitation letter routinely used to invite eligible individuals to cervical cancer screening. The standard letter provides information about the screening programme and instructions for attending screening. The letter will be sent once digitally via the electronic health platforms heilsuvera.is and island.is. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participation rate in the national cervical cancer screening program in Iceland
Time Frame: From the date the invitation is sent through 6 months post-invitation.
|
The primary outcome of this study will be the participation rate in the Icelandic national cervical cancer screening program within 6 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no). |
From the date the invitation is sent through 6 months post-invitation.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participation rate in the national cervical cancer screening program in Iceland
Time Frame: From the date the invitation is sent through 3 months post-invitation.
|
The secondary outcome will be the participation rate in the Icelandic national cervical cancer screening program within 3 months of invitation, defined as a registered cervical sample in the Icelandic Cancer Screening Register. Participation will be coded as a binary variable (yes/no). |
From the date the invitation is sent through 3 months post-invitation.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ágúst Ingi Ágústsson, Cand. Med., Cancer Screening Coordination Center, Primary Health Care of the Capital Area
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Neoplasms
- Uterine Cervical Neoplasms
Other Study ID Numbers
- PHCI-2026-001
- 101162959 (Other Grant/Funding Number: EU4Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.